HOME > TOP STORIES

TOP STORIES

REGULATORY Spinraza Add’l Indication Reported to MHLW Panel, Setting Stage for Its Use in All SMA Patients

September 4, 2017
REGULATORY Programs Funded by MA Holder or Its Subsidiaries Subject to Regulations under Clinical Research Law

September 1, 2017
BUSINESS Daiichi Sankyo Denies Report on AZ’s Acquisition Offer

September 1, 2017
BUSINESS Daiichi Sankyo Share Trade Halted after Report on AZ’s Acquisition Offer

August 31, 2017
BUSINESS Fujifilm Holdings Aims to Achieve 500 Billion Yen in Healthcare Sales in FY2019

August 31, 2017
ACADEMIA Over 150 Clinical Trials of Epigenetic Drugs, Some with Novel Mechanisms of Action, Underway Worldwide

August 31, 2017
REGULATORY MHLW to Form Study Group to Address Leftover Vial Drug Issue, Weighs Multi-Dose Vials

August 30, 2017
BUSINESS Mitsubishi Tanabe to Create New Business by Fusing LLPs with Digital Technologies

August 30, 2017
REGULATORY New Minister Has Hopes for Pharma Industry in Both Medical and Economic Fronts, Wants to Balance Innovation and Cost

August 29, 2017
REGULATORY Opdivo’s Gastric Cancer Use, Avelumab and More Up for MHLW Panel Review/Report on Sept. 8

August 28, 2017
BUSINESS Spinraza to Hit Japan Market on August 30

August 28, 2017
REGULATORY MHLW Seeks 31.4 Trillion Yen in FY2018 Budget, 630 Billion Yen in Natural Rise for Social Security

August 25, 2017
REGULATORY Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too

August 24, 2017
REGULATORY Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30

August 23, 2017
BUSINESS External Activities of Takeda Unit Axcelead to Go Full Throttle This Autumn: President

August 23, 2017
TRENDS Japan Generic Market Decelerating, 3 Majors Log Only Slight Uptick in April-June

August 22, 2017
REGULATORY MHLW Study Group to Expand Investigation to Clinics to Determine Causes of Improper Promotional Activities

August 22, 2017
REGULATORY Clinical Research Law to Apply to Indirectly Funded Programs Too, MHLW to Clarify Procedures: Official

August 21, 2017
TRENDS Pharmas’ Rep Number Corrections in Full Force amid Bleak Market Outlook, Silver Lining Seen in “Specialty” Arena

August 18, 2017
BUSINESS Harvoni Top-Selling Drug in Japan in FY2016, Opdivo Jumps but Drop Expected for FY2017: Jiho Tally

August 17, 2017

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…